Impact of lung metastases on overall survival in the phase 3 SELECT study of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer

RECOMMENDED

Endocrine and Neuroendocrine Tumors (NET)

Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer

Eur J Cancer.

Tahara M, Brose MS, Wirth LJ, Suzuki T, Miyagishi H, Fujino K, Dutcus CE, Gianoukakis A

doi: 10.1016/j.ejca.2018.10.002.

Endocrine and Neuroendocrine Tumors (NET)Head and Neck Cancer

A randomized, phase 3 study of lenvatinib in Chinese patients with radioiodine-refractory differentiated thyroid cancer

Clin Cancer Res

Zheng X, Xu Z, Ji Q, Ge M, Shi F, Qin J, Wang F, Chen G, Zhang Y, Huang R, Tan J, Huang T, Li S, Lv Z, Lin Y, Guo Z, Kubota T, Suzuki T, Ikezawa H, Gao M

doi: 10.1158/1078-0432.CCR-21-0761

Breast Cancer

Recent Developments in Metastatic Breast Cancer

healthbook TIMES Oncology Hematology

Lenvatinib in Advanced Radioiodine-Refractory Thyroid Cancer - A Retrospective Analysis of the Swiss Lenvatinib Named Patient Program

J Cancer.

Balmelli C, Railic N, Siano M, Feuerlein K, Cathomas R, Cristina V, Güthner C, Zimmermann S, Weidner S, Pless M, Stenner F, Rothschild SI

doi: 10.7150/jca.22318.

Lung, Respiratory and Thoracic Cancer

Final Overall Survival, Other Efficacy and Safety Results from ASCEND-3: Phase II Study of Ceritinib in ALKi-Naïve Patients With ALK-Rearranged Non-Small-Cell Lung Cancer

J Thorac Oncol.

Nishio M, Felip E, Orlov S, Park K, Yu CJ, Tsai CM, Cobo M, McKeage M, Su WC, Mok T, Scagliotti GV, Spigel DR, Viraswami-Appanna K, Chen Z, Passos VQ, Shaw AT

doi: 10.1016/j.jtho.2019.11.006.

Head and Neck Cancer

Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial

Lancet Oncol

Brose MS, Robinson B, Sherman SI, Krajewska J, Lin CC, Vaisman F, Hoff AO, Hitre E, Bowles DW, Hernando J, Faoro L, Banerjee K, Oliver JW, Keam B, Capdevila J

doi: 10.1016/S1470-2045(21)00332-6

Lung, Respiratory and Thoracic Cancer

Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study

Lancet Oncol.

Barlesi F, Vansteenkiste J, Spigel D, Ishii H, Garassino M, de Marinis F, Özgüroğlu M, Szczesna A, Polychronis A, Uslu R, Krzakowski M, Lee JS, Calabrò L, Arén Frontera O, Ellers-Lenz B, Bajars M, Ruisi M, Park K

doi: 10.1016/S1470-2045

RECOMMENDED

Gastrointestinal CancerRadio-Oncology

The impact of local control on overall survival after stereotactic body radiotherapy for liver and lung metastases from colorectal cancer: a combined analysis of 388 patients with 500 metastases

BMC Cancer.

Klement RJ, Abbasi-Senger N, Adebahr S, Alheid H, Allgaeuer M, Becker G, Blanck O, Boda-Heggemann J, Brunner T, Duma M, Eble MJ, Ernst I, Gerum S, Habermehl D, Hass P, Henkenberens C, Hildebrandt G, Imhoff D, Kahl H, Klass ND, Krempien R, Lewitzki V, Lohaus F, Ostheimer C, Papachristofilou A, Petersen C, Rieber J, Schneider T, Schrade E, Semrau R, Wachter S, Wittig A, Guckenberger M, Andratschke N

doi: 10.1186/s12885-019-5362-5.

Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer

Onco Targets Ther.

Lorusso L, Pieruzzi L, Biagini A, Sabini E, Valerio L, Giani C, Passannanti P, Pontillo-Contillo B, Battaglia V, Mazzeo S, Molinaro E, Elisei R

doi: 10.2147/OTT.S84625

Related content